Evidence map›Paper›PMID 30753371›Full record

ArticleJournal of Crohn's & colitis2019

Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data From Crohn's Disease Studies.

Remo Panaccione, Robert Löfberg, Paul Rutgeerts, William J Sandborn, Stefan Schreiber, Sofie Berg, Jen-Fue Maa, Joel Petersson, Anne M Robinson, Jean-Frederic Colombel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Crohn's & colitis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Remo PanaccioneUniversity of Calgary, Department of Medicine, Calgary, AB, Canada.
Robert LöfbergIBD Unit, Karolinska Institutet, Stockholm, Sweden.
Paul RutgeertsDivision of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium.
William J SandbornDivision of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Stefan SchreiberDepartment of Medicine I, University Hospital Schleswig-Holstein, Kiel, Germany.
Sofie BergGlobal Medical Affairs, AbbVie AB, Solna, Sweden.
Jen-Fue MaaDevelopment, AbbVie Inc., North Chicago, IL, USA.
Joel PeterssonGlobal Medical Affairs, AbbVie Inc., North Chicago, IL, USA.
Anne M RobinsonDevelopment, AbbVie Inc., North Chicago, IL, USA.
Jean-Frederic ColombelDivision of Gastroenterology, Icahn School of Medicine at Mt Sinai, New York, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsAnalyses of Crohn's Disease [CD] studies of anti-TNF agents, including adalimumab, have reported higher remission rates among patients with shorter disease duration. To further explore the relationship between disease duration and clinical efficacy, we analysed a larger patient cohort.

methodsData were pooled from 10 clinical trials in patients with moderately to severely active CD who received treatment with either adalimumab or placebo. Analyses of efficacy using Crohn's Disease Activity Index [CDAI] endpoints [remission, clinical response [CR]-70, CR-100, patient-reported outcome [PRO] remission] or Harvey-Bradshaw Index [HBI] endpoints [remission/response] were conducted for induction and maintenance treatment periods. Logistic regression was used for comparisons between adalimumab and placebo treatment. Cochran-Armitage trend tests were used for comparisons between disease-duration subgroups [<1 year, ≥1-<2 years, 2-≤5 years, and >5 years].

resultsDuring induction, the proportion of patients achieving CDAI remission was higher in adalimumab- versus placebo-treated patients [p <0.001] and was highest [adalimumab: 45.8%] in the <1 year subgroup compared with longer disease-duration subgroups [≥1-<2 years: 31.0%; 2-≤5 years: 23.1%; >5 years: 23.6%, Cochran-Armitage p = 0.026]. In the majority of maintenance treatment analyses, patients with <1 year disease duration had the highest efficacy responses, with statistically significant differences in remission rates across disease-duration subgroups.

conclusionsThis analysis demonstrates that earlier initiation of adalimumab treatment shortly after diagnosis in patients with moderately to severely active CD leads to improved long-term clinical outcomes.

Indexed as

AdalimumabAdultAnti-Inflammatory AgentsClinical Trials as TopicCrohn DiseaseFemaleHumansMaleTime FactorsTreatment OutcomeTumor Necrosis Factor-alphaAdalimumabAnti-Inflammatory AgentsTumor Necrosis Factor-alphaAdalimumabCrohn’s diseasedisease duration

Identifiers

PMID30753371
PMCPMC6535500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.